Literature DB >> 18836717

Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.

Tamson V Moore1, Gretchen E Lyons, Natasha Brasic, Jeffrey J Roszkowski, Simon Voelkl, Andreas Mackensen, W Martin Kast, I Caroline Le Poole, Michael I Nishimura.   

Abstract

Effective immunotherapy using T cell receptor (TCR) gene-modified T cells requires an understanding of the relationship between TCR affinity and functional avidity of T cells. In this study, we evaluate the relative affinity of two TCRs isolated from HLA-A2-restricted, gp100-reactive T cell clones with extremely high functional avidity. Furthermore, one of these T cell clones, was CD4- CD8- indicating that antigen recognition by this clone was CD8 independent. However, when these TCRs were expressed in CD8- Jurkat cells, the resulting Jurkat cells recognized gp100:209-217 peptide loaded T2 cells and had high functional avidity, but could not recognize HLA-A2+ melanoma cells expressing gp100. Tumor cell recognition by Jurkat cells expressing these TCRs could not be induced by exogenously loading the tumor cells with the native gp100:209-217 peptide. These results indicate that functional avidity of a T cell does not necessarily correlate with TCR affinity and CD8-independent antigen recognition by a T cell does not always mean its TCR will transfer CD8-independence to other effector cells. The implications of these findings are that T cells can modulate their functional avidity independent of the affinity of their TCRs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18836717      PMCID: PMC2773431          DOI: 10.1007/s00262-008-0594-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  51 in total

1.  A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes.

Authors:  B Ortmann; J Copeman; P J Lehner; B Sadasivan; J A Herberg; A G Grandea; S R Riddell; R Tampé; T Spies; J Trowsdale; P Cresswell
Journal:  Science       Date:  1997-08-29       Impact factor: 47.728

Review 2.  A new era for cancer immunotherapy based on the genes that encode cancer antigens.

Authors:  S A Rosenberg
Journal:  Immunity       Date:  1999-03       Impact factor: 31.745

3.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

4.  Full activation of the T cell receptor requires both clustering and conformational changes at CD3.

Authors:  Susana Minguet; Mahima Swamy; Balbino Alarcón; Immanuel F Luescher; Wolfgang W A Schamel
Journal:  Immunity       Date:  2006-12-21       Impact factor: 31.745

5.  MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.

Authors:  M I Nishimura; D Avichezer; M C Custer; C S Lee; C Chen; M R Parkhurst; R A Diamond; P F Robbins; D J Schwartzentruber; S A Rosenberg
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

6.  Influence of human CD8 on antigen recognition by T-cell receptor-transduced cells.

Authors:  Gretchen E Lyons; Tamson Moore; Natasha Brasic; Mingli Li; Jeffrey J Roszkowski; Michael I Nishimura
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

7.  Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.

Authors:  T M Clay; M C Custer; J Sachs; P Hwu; S A Rosenberg; M I Nishimura
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

Review 8.  Molecular mechanisms of MHC class I abnormalities and APM components in human tumors.

Authors:  Barbara Seliger
Journal:  Cancer Immunol Immunother       Date:  2008-04-12       Impact factor: 6.968

9.  A T-cell receptor associated with naturally occurring human tumor immunity.

Authors:  Bianca D Santomasso; Wendy K Roberts; Ashby Thomas; Travis Williams; Nathalie E Blachère; Mark E Dudley; Alan N Houghton; Jerome B Posner; Robert B Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

10.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.

Authors:  H J Zeh; D Perry-Lalley; M E Dudley; S A Rosenberg; J C Yang
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

View more
  12 in total

1.  Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells.

Authors:  Timothy T Spear; Yuan Wang; Kendra C Foley; David C Murray; Gina M Scurti; Patricia E Simms; Elizabeth Garrett-Mayer; Lance M Hellman; Brian M Baker; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2017-06-20       Impact factor: 6.968

2.  Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.

Authors:  Jennifer N Uram; Chelsea M Black; Emilee Flynn; Lanqing Huang; Todd D Armstrong; Elizabeth M Jaffee
Journal:  J Immunol       Date:  2011-02-23       Impact factor: 5.422

3.  Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.

Authors:  Marie T Kim; Martin J Richer; Brett P Gross; Lyse A Norian; Vladimir P Badovinac; John T Harty
Journal:  J Immunol       Date:  2015-09-25       Impact factor: 5.422

Review 4.  The promise and potential pitfalls of chimeric antigen receptors.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Curr Opin Immunol       Date:  2009-03-25       Impact factor: 7.486

5.  Molecular properties of gp100-reactive T-cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells.

Authors:  Jonathan M Eby; Angela R Smith; Timothy P Riley; Cormac Cosgrove; Christian M Ankney; Steven W Henning; Chrystal M Paulos; Elizabeth Garrett-Mayer; Rosalie M Luiten; Michael I Nishimura; Brian M Baker; I Caroline Le Poole
Journal:  Pigment Cell Melanoma Res       Date:  2018-08-13       Impact factor: 4.693

Review 6.  Constant regulation for stable CD8 T-cell functional avidity and its possible implications for cancer immunotherapy.

Authors:  Connie B Gilfillan; Michael Hebeisen; Nathalie Rufer; Daniel E Speiser
Journal:  Eur J Immunol       Date:  2021-03-30       Impact factor: 5.532

7.  Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity.

Authors:  Yi Zhang; Yeuying Liu; Kelly M Moxley; Lucy Golden-Mason; Michael G Hughes; Tongxin Liu; Mirjam H M Heemskerk; Hugo R Rosen; Michael I Nishimura
Journal:  PLoS Pathog       Date:  2010-07-29       Impact factor: 6.823

8.  Structurally silent peptide anchor modifications allosterically modulate T cell recognition in a receptor-dependent manner.

Authors:  Angela R Smith; Jesus A Alonso; Cory M Ayres; Nishant K Singh; Lance M Hellman; Brian M Baker
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-26       Impact factor: 12.779

9.  Functional cloning of a gp100-reactive T-cell receptor from vitiligo patient skin.

Authors:  Jared Klarquist; Jonathan M Eby; Steven W Henning; Mingli Li; Derek A Wainwright; Wiete Westerhof; Rosalie M Luiten; Michael I Nishimura; I Caroline Le Poole
Journal:  Pigment Cell Melanoma Res       Date:  2016-03-04       Impact factor: 4.693

10.  Murine CD8 T-cell functional avidity is stable in vivo but not in vitro: Independence from homologous prime/boost time interval and antigen density.

Authors:  Connie B Gilfillan; Chensu Wang; Mona O Mohsen; Nathalie Rufer; Michael Hebeisen; Mathilde Allard; Grégory Verdeil; Darrell J Irvine; Martin F Bachmann; Daniel E Speiser
Journal:  Eur J Immunol       Date:  2019-12-10       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.